Abbott Laboratories (ABT) fair value analysis

S&P 500 · Updated 2026-09-07

Abbott Laboratories is a diversified healthcare company that manufactures and sells pharmaceuticals, medical devices, diagnostics, and nutritional products for human health. The company operates globally across multiple continents, serving healthcare providers, patients, and consumers in countries around the world.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, ABT is trading at a 10–25% discount to estimated fair value.

ABT currently ranks #40 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $108.33
Sector: Healthcare
12-month range: $87.78–$128.01

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: B
Leverage: Low
Margin trend: Expanding
Revenue growth: Modest
RSI zone: Neutral
52-week position: The upper-middle quarter of its range
DCF cross-check: Overvalued

What our data shows for ABT

Our model validated 17 trailing price-to-earnings windows for ABT, built from quarterly earnings records.
Shares are trading in the middle of their 12-month price range of $87.78–$128.01.
The 14-day relative strength index sits at a neutral 50.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for ABT
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent ABT news

TickrTrends' derived news-sentiment signal for ABT is currently leaning positive, computed from recent coverage.

Boston Scientific Says Unlikely to Meet 2026 Forecast After Cyberattack Disruption (insurancejournal.com, 2026-09-08)
TickrTrends take: Abbott Laboratories operates in the Healthcare sector where operational disruptions can have material impacts on financial performance and investor confidence. Boston Scientific's recent cyberattack and subsequent withdrawal of 2026 guidance illustrates how unexpected events can pressure companies in this space to revise outlooks, a factor that valuation models must account for when assessing healthcare equipment and pharmaceutical manufacturers. Given TickrTrends' current undervalued assessment of ABT, investors should monitor whether Abbott faces similar operational risks or guidance adjustments that could influence whether the undervaluation thesis remains intact.
If a Stock Market Crash Is Coming, Investors Will Want to Own This Dividend King (finance.yahoo.com, 2026-09-08)
TickrTrends take: Abbott Laboratories maintains the rare status of a Dividend King in the Healthcare sector, a designation that reflects decades of consecutive dividend increases and suggests underlying business stability. Given TickrTrends' current assessment of ABT as undervalued, the combination of defensive dividend characteristics with potential price appreciation could appeal to investors seeking both income and capital gains during market uncertainty. Valuation-focused readers should monitor whether ABT's dividend reliability continues to support its stock during broader market volatility, as sustained payout capacity often reflects the strength of underlying business fundamentals.
Two Recessions Couldn’t Stop These 4 Healthcare Stocks From Raising Dividends (finance.yahoo.com, 2026-08-31)
TickrTrends take: Abbott Laboratories is among healthcare stocks that maintained dividend growth through challenging economic periods, which aligns with the defensive characteristics typically valued in recession-resistant companies. Given TickrTrends' undervalued assessment, this demonstrated resilience in shareholder returns may be relevant to investors evaluating the company's ability to sustain capital returns during market downturns. A valuation-focused reader should monitor whether ABT's dividend sustainability correlates with the broader valuation discount the platform has identified.

What people are saying

Follow the ABT conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is ABT stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), ABT is trading at a 10–25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is ABT's TickrTrends verdict?

ABT's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does ABT compare to other Healthcare stocks?

ABT ranks #40 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is ABT overbought or oversold?

ABT's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

ABT vs BTSG · ABT vs COLL · ABT vs DVA · ABT vs INCY · ABT vs LMAT